As you can see, GNPX has been trending vertically since the end of November.
At this moment, GNPX is trading over 3 key lines of potential support which could provide confidence for a continued move up the charts.
Those 3 lines are:
- 50-Day Simple Moving Average
- 200-Day Simple Moving Average
- 13-Day Exponential Moving Average
With this potential support below GNPX, this recent uptrend could be the start of something special...
No. 2 Potential GNPX Driver Indicator
Right now, according to Barchart, GNPX is displaying several technical triggered as bullish. They are GNPX's:
Short Term Indicators
- 20 Day Moving Average
- 20 - 50 Day MACD Oscillator
- 20 - 200 Day MACD Oscillator
Medium Term Indicators
- 50 Day Moving Average
- 50 - 200 Day MACD Oscillator
Long Term Indicators
- 100 Day Moving Average
- 150 Day Moving Average
- 200 Day Moving Average
- 100 - 200 Day MACD Oscillator
Additionally, Barchart's "TrendSpotter" composite technical indicator is also triggered as a "BUY."
The website sees GNPX as a "56% BUY" based on overall technicals which is considerably up compared to the site's "56% SELL" recommendation from last month.
Keep an eye on these technical indicators closely as they may signal GNPX's next breakout if more become triggered.
-----
No. 3 Potential GNPX Driver Indicator
James Molloy of Alliance Global Partners issued a new price target on April 22nd of 2020.
At the time, the stock was trading at $1.99. He initiated coverage and provided an $8.00 price target.
As of Monday's closing valuation of $3.98, GNPX is now displaying upside potential of 101% to that target.
Remember, it was just earlier this year that we saw GNPX climb over the $7.00+ level when I brought it to your attention in February.
Could this stock's next big run be right around the corner?
Additionally, another analyst, Cosme Ordonez from Noble Financial has also pegged GNPX with a $5.00 target.
From Wednesday's close of $3.98, that provides GNPX with upside potential of 25%.
Now, I'm not saying that GNPX is going to be running to either of those targets today, but you need to be aware of the potential upside for this profile.
-----
No. 4 Potential GNPX Driver Indicator
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
Successful Completion of Engineering Batch with Transfer from Research Institution to Commercial Contract Development and Manufacturing Organizations with Clinical Production Underway
Manufacturing Technology Transfer Marks Major Company Milestone
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has successfully completed the technology transfer of its manufacturing process for the production of REQORSA™ immunogene therapy, the Company’s lead drug candidate, from the major cancer research institution where it was previously manufactured to experienced, commercial Contract Development and Manufacturing Organizations (CDMOs).
The completed technology transfer marks a significant achievement for Genprex. For the first time, REQORSA was manufactured at commercial scale in a current Good Manufacturing Practices (cGMP) compliant facility, outside of the research institution where REQORSA was discovered. The Company believes production and process improvements will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. The Company believes that it is on track to complete manufacturing of clinical grade REQORSA to supply the Company’s upcoming Acclaim-1 and Acclaim-2 clinical trials that combine REQORSA with Tagrisso® (marketed by AstraZeneca) and with Keytruda® (marketed by Merck & Co., Inc.), respectively, both of which are on track to be initiated in the first-half 2021.
"The successful completion of our manufacturing technology transfer represents a major milestone for Genprex," said Rodney Varner, President and Chief Executive Officer of Genprex. "We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials."
Read the full article here.
-----
No. 5 Potential GNPX Driver Indicator
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Approval of new name marks important branding milestone and aligns with the program’s overall progress
REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX™ nanoparticle delivery system to deliver cancer-fighting genes
FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® for the treatment of non-small cell lung cancer earlier this year
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REQORSA™ for its lead drug candidate in development for the treatment of non-small cell lung cancer, known previously by the laboratory designation GPX-001.
The name REQORSA (pronounced "re-KORE-suh"), was developed in accordance with FDA’s guidance for the submission and evaluation of proprietary names. The Company selected the name based on comprehensive and disciplined review of name candidates, including a research study of healthcare practitioners across the U.S. to ensure accurate prescription and safety interpretation of the name.
"We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer," said Rodney Varner, President and Chief Executive Officer of Genprex. "This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission."
Read the full article here.
-----
No. 6 Potential GNPX Driver Indicator
According to Yahoo Finance, GNPX currently has an approximate 32.48Mn shares in its float.
As we've seen in previous stock profiles, including this one when I brought it to you back in February (approximately 336% surge in roughly two weeks) and July (approximately 30% in 2 days), a low float can lead to explosive vertical surges in the short-term from volatility.
Biotech stocks can be very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.
Could the next big news coming from the GNPX camp be the spark to send share prices vertical?
-----
More About The Company: Genprex, Inc.
From the company website:
Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and diabetes.
The company’s lead product candidate, REQORSA™ immunogene therapy (quaratusugene ozeplasmid), is being developed for non-small cell lung cancer (NSCLC). The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. REQORSA uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.
-----
Top GNPX Potential Driver Indicators Recap
#1. GNPX Trading Over Key Lines Of Support
#2. Bullish Technical Indicators
#3. Analyst Coverage/Price Targets
#4. Company Completes Manufacturing Technology Transfer
#5. Receives Conditional FDA Acceptance of Proprietary Name
#6. GNPX's Low Float
-----
If there are any updates today, I'll get them out to you quickly.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)
